DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
IPI-493 is an investigational drug.
There have been 102 clinical trials for IPI-493. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Amgen, and Lymphoma Study Association.
Recent Clinical Trials for IPI-493
|Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation||Academic Medical Organization of Southwestern Ontario||Phase 1|
|Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation||Lawson Health Research Institute||Phase 1|
|Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma||The V Foundation for Cancer Research||Phase 2|